| Kelsey E Olson, PT | |
|
3200 E Racine St, Janesville, WI 53546-2343 | |
| (608) 373-8790 | |
| (608) 371-8935 |
| Full Name | Kelsey E Olson |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 3200 E Racine St, Janesville, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053829390 | NPI | - | NPPES |
| 1053829390 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 10886 (Minnesota) | Secondary |
| 225100000X | Physical Therapist | 15700-24 (Wisconsin) | Primary |
| Provider Name | Dean Health Systems Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1053358846 PECOS PAC ID: 7012827983 Enrollment ID: O20031105000584 |
News Archive
Talking with other people in a friendly way can make it easier to solve common problems, a new University of Michigan study shows. But conversations that are competitive in tone, rather than cooperative, have no cognitive benefits.
Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it signed an amendment to its contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix, Inc., a leading firm known for its pioneering HALO analysis platform for stem cells.
New research from Texas A&M University and Texas State University found that older adults who participate in gardening may be more likely to eat their veggies.
Two of the world's leading universities are joining forces to combine neuroscience and engineering in order to alleviate human suffering caused by such neurological disabilities as paralysis and deafness. Scientists, engineers, and clinicians at Harvard Medical School (HMS) and Ecole Polytechnique F-d-rale de Lausanne (EPFL) will collaborate on six pioneering neuroengineering projects made possible thanks to a $3.6 million grant from the Bertarelli Foundation.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
› Verified 1 days ago
| Provider Name | Mercy Health System Corporation |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1598718603 PECOS PAC ID: 7416860440 Enrollment ID: O20031113000164 |
News Archive
Talking with other people in a friendly way can make it easier to solve common problems, a new University of Michigan study shows. But conversations that are competitive in tone, rather than cooperative, have no cognitive benefits.
Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it signed an amendment to its contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix, Inc., a leading firm known for its pioneering HALO analysis platform for stem cells.
New research from Texas A&M University and Texas State University found that older adults who participate in gardening may be more likely to eat their veggies.
Two of the world's leading universities are joining forces to combine neuroscience and engineering in order to alleviate human suffering caused by such neurological disabilities as paralysis and deafness. Scientists, engineers, and clinicians at Harvard Medical School (HMS) and Ecole Polytechnique F-d-rale de Lausanne (EPFL) will collaborate on six pioneering neuroengineering projects made possible thanks to a $3.6 million grant from the Bertarelli Foundation.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelsey E Olson, PT 3200 E Racine St, Janesville, WI 53546-2343 Ph: (608) 373-8790 | Kelsey E Olson, PT 3200 E Racine St, Janesville, WI 53546-2343 Ph: (608) 373-8790 |
News Archive
Talking with other people in a friendly way can make it easier to solve common problems, a new University of Michigan study shows. But conversations that are competitive in tone, rather than cooperative, have no cognitive benefits.
Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it signed an amendment to its contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix, Inc., a leading firm known for its pioneering HALO analysis platform for stem cells.
New research from Texas A&M University and Texas State University found that older adults who participate in gardening may be more likely to eat their veggies.
Two of the world's leading universities are joining forces to combine neuroscience and engineering in order to alleviate human suffering caused by such neurological disabilities as paralysis and deafness. Scientists, engineers, and clinicians at Harvard Medical School (HMS) and Ecole Polytechnique F-d-rale de Lausanne (EPFL) will collaborate on six pioneering neuroengineering projects made possible thanks to a $3.6 million grant from the Bertarelli Foundation.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
› Verified 1 days ago
Alesia L Drake, DPT, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6842 Fax: 608-741-6953 | |
Macy G Bolt, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3200 E Racine St, Janesville, WI 53546 Phone: 608-371-8000 Fax: 608-371-8935 | |
Ann Slinde, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2050 Morse Street Suite 150, Janesville, WI 53545 Phone: 608-305-1028 Fax: 608-554-4787 | |
Joshua T Lehr, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3524 E Milwaukee St, Janesville, WI 53546 Phone: 608-756-7100 Fax: 608-756-7225 | |
Marcus A Sojka, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 3200 E Racine St, Janesville, WI 53546 Phone: 608-371-8000 Fax: 608-371-8935 | |
Peter W. Menges, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 557 N Washington St, Janesville, WI 53548 Phone: 608-754-6000 Fax: 608-755-7892 |